Amgen partners with Genenta, San Raffaele on an anti-tumor drug


Pierluigi Paracchi, Genata

The gene therapy experts at Italy’s San Raffaele Hospital and Scientific Institute (Ospedale San Raffaele, OSR) and its spinout Genenta Sciences are collaborating with Amgen on new tumor programs. The partners will “develop an innovative therapy based on gene transfer into autologous hematopoietic Stem Cells to express specific anti-tumor proteins in their progeny.” “Amgen is the perfect partner for us due to their leadership in oncology and commitment in exploring innovative technologies,” stated Pierluigi Paracchi, Genenta’s Chairman and Chief Executive Officer. “We are proud to announce this collaboration to exploit our HSCs gene therapy platform.”

Eli Lilly has won CHMP support for the conditional approval of its sarcoma drug olaratumab. The pharma giant’s first conditional approval in the EU will likely follow within a few months. Lilly has also filed for an approval at the FDA, which has provided a breakthrough therapy designation for the drug.

Aerie Pharmaceuticals has juster raised $125 million through the sale of stock. Its shares rocketed up a couple of days ago on positive glaucoma data.

Novartis’s new position on selling Alcon? Never say never.

The Cambridge, MA-based micro biome player Synlogic has been filling out its executive crew. New staffers:

  • Todd E. Shegog, chief financial officer
  • Aoife M. Brennan, M.D., chief medical officer
  • Caroline B. Kurtz, Ph.D., head of translational sciences and product development
  • Richard M. Schwartz, Ph.D., senior vice president, process development and manufacturing

Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 13,500+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy